Drugs / TQ-A3334
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06160895 | Dec 2023 → Jun 2024 | hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06507891 | Jul 2020 → Aug 2023 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04273815 | Jul 2020 → Jan 2021 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04202653 | Jan 2020 → Jun 2023 | chronic hepatitis B virus infection | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04180150 | Nov 2019 → Sep 2020 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06706310 Comparator | Dec 2024 → Dec 2025 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ-A3334 | “Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection” NCT06706310 ↗ |
| Action | Activate | “TQ-A3334 is a kind of TLR7 receptor agonist.” NCT04180150 ↗ |
| Modality | Other / unclassified | “TLR-7 agonist” NCT04273815 ↗ |
| Route | Oral | “TQ-A3334 po qw” NCT04202653 ↗ |
| Target | TLR7 | “TQ-A3334 is a kind of TLR7 receptor agonist.” NCT04180150 ↗ |